Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sanofi - American Depositary Shares
(NQ:
SNY
)
49.31
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 2, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Sanofi - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
32
33
Next >
Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
June 28, 2025
Nektar Therapeutics soared 157% after Rezpeg succeeded in a Phase 2b eczema trial. Analysts forecast huge upside—here’s why there could be more gains ahead.
Via
MarketBeat
Why This Biotech Stock Just Doubled In A Single Day
June 26, 2025
Vor Biopharma shares surge 43% after licensing deal, $175M raise, and CEO transition.
Via
Benzinga
Why Is Nektar Therapeutics Stock Trading Higher On Wednesday?
June 25, 2025
Nektar's rezpegaldesleukin met key efficacy targets in a mid-stage eczema study, though analysts flagged safety and differentiation concerns.
Via
Benzinga
Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies
June 25, 2025
Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases.
Via
Benzinga
SANOFI-ADR (NASDAQ:SNY) - A Reliable Dividend Stock with Strong Fundamentals
June 05, 2025
Via
Chartmill
Why Is Cidara Therapeutics Stock Trading Higher On Monday?
June 23, 2025
Cidara's CD388 met key goals in a Phase 2b flu trial, showing strong efficacy and safety data, with FDA talks planned for advancing to Phase 3.
Via
Benzinga
FDA Approves Regeneron Sanofi Treatment For Rare Autoimmune Skin Disorder
June 20, 2025
Dupixent approved by FDA for bullous pemphigoid, offering a new option for adults with the rare autoimmune skin disease following positive trial results.
Via
Benzinga
Regeneron, Sanofi Say Their Inflammation Drug Approved By FDA For Rare Skin Disease Affecting Elderly, But Retail Stays Dull
June 20, 2025
The injection is now approved in the U.S. to treat eight distinct diseases with underlying type 2 inflammation.
Via
Stocktwits
Topics
Supply Chain
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
June 12, 2025
Three relatively unknown biopharma firms receive near-unanimous approval from analysts for their promising drug candidates in development.
Via
MarketBeat
Novavax's Experimental COVID-19-Influenza Combo Shot Shows Immune Response Among Older Adults In Phase 3 Trial
June 11, 2025
Novavax's combo and standalone flu vaccines showed strong immune responses and good safety in a Phase 3 trial of adults 65 and older.
Via
Benzinga
American Pharmacists Association Withholds Endorsement Of CDC's Revised COVID-19 Vaccine Guidance
June 10, 2025
The American Pharmacists Association announced Monday it will withhold endorsement of the CDC's updated immunization schedule.
Via
Benzinga
Vaccine Stocks Moderna, Pfizer Hit After A Surprise Blow From RFK Jr.
June 09, 2025
A CDC committee in charge of making vaccine recommendations was gutted Monday to make way for a new coalition.
Via
Investor's Business Daily
Topics
Government
Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season
June 09, 2025
Sanofi boosts Beyfortus output for RSV season while Dupixent trial shows strong eczema relief in patients with skin of color.
Via
Benzinga
Applied Digital And Riot Platforms Are Among Top 10 Mid-Cap Gainers Last Week (Jun 2-Jun 6): Are The Others In Your Portfolio?
June 08, 2025
Via
Benzinga
Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta
June 06, 2025
Byron Allen dials out, Salesforce logs in. Here are the various deal announcements of the past week plus bankruptcy updates.
Via
Benzinga
Topics
Bankruptcy
RFK Jr. Champions 'Medical Freedom' While Curtailing Access, Say Public Health Experts
June 06, 2025
U.S. Health Secretary Robert F. Kennedy Jr. has championed "medical freedom" while simultaneously limiting access to COVID-19 vaccines and restricting food stamp purchases, creating what public health...
Via
Benzinga
Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response
June 02, 2025
Kymera's KT-621 achieved rapid, deep STAT6 degradation and showed a strong safety profile in Phase 1, with the next trials planned through early 2026.
Via
Benzinga
Sanofi To Buy Blueprint Medicines For Up To $9.5B: Retail Sees More Acquisition Offers From European Pharma Companies
June 02, 2025
Sanofi will pay $129 per share in cash at closing, representing a 27% premium to Blueprint’s closing price on Friday of $101.35.
Via
Stocktwits
Moderna's New COVID Vaccine Secures FDA-Clearance For Seniors, At-Risk Individuals
June 02, 2025
Moderna's mNexspike COVID vaccine approved by FDA for older adults and at-risk groups after Phase 3 trial shows improved efficacy and safety profile.
Via
Benzinga
Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout
June 02, 2025
Sanofi will acquire Blueprint Medicines for up to $9.5 billion, gaining Ayvakit and a promising immunology pipeline, including BLU-808 and elenestinib.
Via
Benzinga
Why Blueprint Medicines Shares Are Trading Higher By 27%; Here Are 20 Stocks Moving Premarket
June 02, 2025
Via
Benzinga
US Stocks Likely To Open Lower After A Solid May: 'TACO' Trade And 'Run It Hot' Optimism 'Are Consensus At This Point,' Says Expert
June 02, 2025
U.S. stock futures fell on Monday after a mixed close on Friday. Futures of major benchmark indices were trading lower in premarket.
Via
Benzinga
Campbell's, SAIC And 3 Stocks To Watch Heading Into Monday
June 02, 2025
Via
Benzinga
Benzinga Bulls And Bears: Nvidia, Palantir, Marvell Technology — And Markets Rallied In May
May 31, 2025
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
Via
Benzinga
Regeneron Pharmaceuticals Crashes 12% On A Surprise Sanofi-Tied Failure
May 30, 2025
Regeneron stock crashed Friday after the company's Sanofi-partnered COPD treatment unexpectedly failed in a Phase 3 study.
Via
Investor's Business Daily
Regeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Data
May 30, 2025
Regeneron and Sanofi's COPD drug itepekimab cut exacerbations by 27% in one Phase 3 trial, while the second trial did not meet its main goal.
Via
Benzinga
Robert F. Kennedy Jr. Says CDC Drops COVID Vaccine For 'Healthy' Pregnant Women, Children
May 27, 2025
RFK Jr. says the COVID-19 vaccine is no longer on the CDC's recommended schedule for healthy kids and pregnant women, though the official site still shows it listed.
Via
Benzinga
Sanofi, VNVC Launch Vaccine Manufacturing Facility In Vietnam, Says Report: Retail’s Positive
May 27, 2025
According to Reuters, operations at the new facility are expected to begin by the end of 2027.
Via
Stocktwits
SANOFI-ADR (NASDAQ:SNY) – A Pharmaceutical Stock With Undervalued Potential
May 26, 2025
SANOFI-ADR (SNY) offers strong profitability, an attractive dividend, and undervalued metrics, making it a compelling choice for value investors in the pharmaceutical sector.
Via
Chartmill
Analysts Think These Stocks Could More Than Double in Value
May 23, 2025
Septerna, Intellia, and Novavax have garnered investor attention for their significant upside potential, but investors should beware the risks as well.
Via
MarketBeat
Topics
World Trade
< Previous
1
2
3
4
5
6
7
8
9
...
32
33
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.